• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Latest News

Philip Mease, MD, Discusses Head-to-Head BE BOLD Clinical Trial
Philip Mease, MD, Discusses Head-to-Head BE BOLD Clinical Trial

October 10th 2024

Mease, the lead investigator on the trial, spoke about comparing varying mechanisms of action, primary and secondary endpoints, and how the results of BE BOLD could affect treatment choices.

Benzene in Benzoyl Peroxide at Room Temperature: What Comes Next?
Benzene in Benzoyl Peroxide at Room Temperature: What Comes Next?

October 10th 2024

Bimekizumab Demonstrates Safety and Efficacy in Elderly Patients with Psoriasis
Bimekizumab Demonstrates Safety and Efficacy in Elderly Patients with Psoriasis

October 10th 2024

Evan Rieder, MD: Immersion in the Eczema Patient Experience
Evan Rieder, MD: Immersion in the Eczema Patient Experience

October 10th 2024

Highly Prevalent, Scarcely Supported: Common Skin Issues Remain Underserved
Highly Prevalent, Scarcely Supported: Common Skin Issues Remain Underserved

October 10th 2024

Navigating CSU Diagnosis: Best Practices
Meet the 2024 Quarterly Editor in Chiefs
Subscribe Now for Free - eNL
Explore Our Conference Coverage
Subscribe for Free - Print
Stay Informed!
Don't miss the latest in dermatology news
2

Conference Coverage

View All
Highly Prevalent, Scarcely Supported: Common Skin Issues Remain Underserved
Highly Prevalent, Scarcely Supported: Common Skin Issues Remain Underserved

October 10th 2024

Phase 2b Trial Reinforces Zasocitinib’s Safety Profile
Phase 2b Trial Reinforces Zasocitinib’s Safety Profile

October 8th 2024

Tralokinumab Shows Long-Term Efficacy for AD in Sensitive Areas
Tralokinumab Shows Long-Term Efficacy for AD in Sensitive Areas

October 7th 2024

Join Your Dermatology NP/PA Community at the Elevate Derm PA NP Conference
Join Your Dermatology NP/PA Community at the Elevate Derm PA NP Conference

October 7th 2024

Latest Videos

All News

© 2024 MJH Life Sciences

All rights reserved.